Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2013, Article ID 351292, 5 pages
http://dx.doi.org/10.1155/2013/351292
Case Report

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma

1Division of Hematology and Oncology, Department of Medicine, Edah Hospital, No. 1, Yi-Da Road, Yen-Tsao District, P.O. Box 824, Kaohsiung, Taiwan
2Department of Radiation Oncology, Edah Hospital, Kaohsiung, Taiwan
3Department of Nuclear Medicine, Edah Hospital, Kaohsiung, Taiwan

Received 15 July 2013; Accepted 12 September 2013

Academic Editors: R. Lowenthal and M. Nagasawa

Copyright © 2013 Hung-Bo Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Kuruvilla, “Standard therapy of advanced Hodgkin lymphoma,” Hematology, pp. 497–506, 2009. View at Google Scholar · View at Scopus
  2. J. M. Connors, “More is not necessarily better when treating Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 29, no. 32, pp. 4215–4216, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Sureda, M. Constans, A. Iriondo et al., “Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse,” Annals of Oncology, vol. 16, no. 4, pp. 625–633, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Fermé, N. Mounier, M. Diviné et al., “Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Études des Lymphomes de l'Adulte H89 trial,” Journal of Clinical Oncology, vol. 20, no. 2, pp. 467–475, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Josting, L. Nogová, J. Franklin et al., “Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group,” Journal of Clinical Oncology, vol. 23, no. 7, pp. 1522–1529, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Campbell, A. Wirth, A. Milner, J. Di Iulio, M. MacManus, and G. Ryan, “Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure,” International Journal of Radiation Oncology Biology Physics, vol. 63, no. 5, pp. 1538–1545, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Kuruvilla, A. Keating, and M. Crump, “How I treat relapsed and refractory Hodgkin lymphoma,” Blood, vol. 117, no. 16, pp. 4208–4217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. D. C. Linch, D. Winfield, A. H. Goldstone et al., “Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial,” The Lancet, vol. 341, no. 8852, pp. 1051–1054, 1993. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Schmitz, B. Pfistner, M. Sextro et al., “Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial,” The Lancet, vol. 359, no. 9323, pp. 2065–2071, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Bonfante, A. Santoro, S. Viviani et al., “Outcome of patients with Hodgkin's disease failing after primary MOPP- ABVD,” Journal of Clinical Oncology, vol. 15, no. 2, pp. 528–534, 1997. View at Google Scholar · View at Scopus
  11. A. Josting, U. Rueffer, J. Franklin, M. Sieber, V. Diehl, and A. Engert, “Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group,” Blood, vol. 96, no. 4, pp. 1280–1286, 2000. View at Google Scholar · View at Scopus
  12. A. Younes, N. L. Bartlett, J. P. Leonard et al., “Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas,” New England Journal of Medicine, vol. 363, no. 19, pp. 1812–1821, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Younes, A. K. Gopal, S. E. Smith et al., “Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 30, no. 18, pp. 2183–2218, 2012. View at Publisher · View at Google Scholar
  14. M. S. Karuturi, S. Arai, R. W. Chen et al., “Overall survival benefit for patients with relapsed Hodgkin lymphoma treated with brentuximab vedotin after autologous stem cell transplant,” in Proceedings of the ASH Annual Meeting Abstracts, vol. 3701, 2012.
  15. A. Gualberto, A. Chi, and Y. Liu, “Activity of the investigational antibody-drug conjugate brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: comparisons with meta-analyses of historical control chemotherapy data,” in Proceedings of the ASH Annual Meeting Abstracts, vol. 4975, 2012.
  16. R. W. Chen, J. M. Palmer, S. H. Thomas et al., “Brentuximab vedotin, (SGN-35) enables successful reduced intensity allogeneic hematopoietic cell transplantation in relapsed/refractory Hodgkin lymphoma,” Blood, vol. 119, no. 26, pp. 6379–6381, 2012. View at Google Scholar
  17. A. K. Gopal, R. Ramchandren, O. A. O'Connor et al., “Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation,” Blood, vol. 120, no. 3, pp. 560–568, 2012. View at Google Scholar